Esophageal squamous cell carcinoma · 3 regimens
Cost vs Efficacy · 1 point
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Cisplatin and nab-Paclitaxel (nab-TP) and Camrelizumab Variant #01 Partial | — | R 38 467 | 21d | — | — | — | — | — |
Cisplatin and Paclitaxel (TP) and Camrelizumab Variant #01 Partial | — | R 1 589 | 21d | ~6.9 mo | ~15.5 mo | ~11 | ~R 17 477 PFS proxy · indirect | 3 |
Cisplatin and Paclitaxel (TP) and Toripalimab Variant #01 Partial | — | R 1 589 | 21d | — | — | — | — | 1 |
3 of 3 regimens shown